- Home
- NUVL vs CWST Comparison
NUVL vs CWST Comparison
Compare NUVL & CWST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVL
- CWST
- Stock Information
- Founded
- NUVL 2017
- CWST 1975
- Country
- NUVL United States
- CWST United States
- Employees
- NUVL N/A
- CWST N/A
- Industry
- NUVL Biotechnology: Pharmaceutical Preparations
- CWST Environmental Services
- Sector
- NUVL Health Care
- CWST Utilities
- Exchange
- NUVL Nasdaq
- CWST Nasdaq
- Market Cap
- NUVL 4.9B
- CWST 5.8B
- IPO Year
- NUVL 2021
- CWST 1997
- Fundamental
- Price
- NUVL $87.24
- CWST $106.45
- Analyst Decision
- NUVL Strong Buy
- CWST Strong Buy
- Analyst Count
- NUVL 10
- CWST 5
- Target Price
- NUVL $112.60
- CWST $111.50
- AVG Volume (30 Days)
- NUVL 492.9K
- CWST 310.5K
- Earning Date
- NUVL 11-12-2024
- CWST 10-30-2024
- Dividend Yield
- NUVL N/A
- CWST N/A
- EPS Growth
- NUVL N/A
- CWST N/A
- EPS
- NUVL N/A
- CWST 0.12
- Revenue
- NUVL N/A
- CWST $1,489,364,000.00
- Revenue This Year
- NUVL N/A
- CWST $24.87
- Revenue Next Year
- NUVL N/A
- CWST $12.16
- P/E Ratio
- NUVL N/A
- CWST $909.64
- Revenue Growth
- NUVL N/A
- CWST 26.53
- 52 Week Low
- NUVL $56.52
- CWST $79.16
- 52 Week High
- NUVL $113.51
- CWST $111.01
- Technical
- Relative Strength Index (RSI)
- NUVL 38.02
- CWST 57.82
- Support Level
- NUVL $89.62
- CWST $106.00
- Resistance Level
- NUVL $96.24
- CWST $111.01
- Average True Range (ATR)
- NUVL 2.90
- CWST 2.31
- MACD
- NUVL -0.27
- CWST 0.56
- Stochastic Oscillator
- NUVL 15.96
- CWST 68.36
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
About CWST Casella Waste Systems Inc.
Casella Waste Systems Inc is a solid waste removal company, providing resource management services to residential, commercial, municipal, and industrial customers. The company's reportable segments on Geographical basis include Eastern, Western and Mid-Atlantic regions through the Resource solution segment. It generates maximum revenue from the Western region segment. The company services include Recycling, Collection, Organics, Energy, Landfills, Special Waste as well as Professional Services.